Secondary analysis of the phase 3 ADRIATIC trial in limited-stage SCLC after chemoradiotherapy: patient-reported quality of life, functioning and symptoms did not differ between consolidation durvalumab (n=264) and placebo (n=266), with small, non-meaningful changes.
Secondary analysis
Novello et al. Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial